Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 2016

View Archived Issues

Mice homozygous for LGMD2I-causing FKRP mutation show progressive myopathy

Genetic association meta-analysis identifies 10 novel risk loci for atopic dermatitis

X-Chem and MD Anderson partner to discover and develop novel cancer therapies

Merck & Co. forms partnership with BH4 pathway modulator developer Quartet Medicine

AGTC and BCM Families Foundation collaborate on AAV-based gene therapy for blue cone monochromacy

BioAtla and Sinobioway select first programs under CAB collaboration in China

EMA will review Trevyent under centralized authorization procedure

U.S. Army starts phase I trial of dengue challenge virus

OBI Pharma's immunotherapy OBI-833 enters first-in-human trial

First patient treated in I trial of SBP-101 for pancreatic cancer

Faron Pharmaceuticals reports topline results from phase II study of Traumakine

Clearside Biomedical reports topline data from phase II study of CLS-TA

Ionis Pharmaceuticals' IONIS-HTT Rx receives FDA orphan drug designation

First-in-class Dub inhibitor shows preclinical antitumor activity

Millendo licenses phase II polycystic ovary syndrome candidate from AstraZeneca

Universite Pierre et Marie Curie discloses DNA gyrase inhibitors

Katholieke Universiteit Leuven and UCB present PI4KIII inhibitors

State University of New Jersey reports antibacterial compounds

New U.K. study investigates tocilizumab for PAH

SYK inhibitor shows acceptable safety profile in patients with DLBCL and FL

Paratek expects results from phase III trial of omadacycline in ABSSSI in mid-2016

FDA grants fast track designation to Bendavia for primary mitochondrial myopathy

Novo Nordisk seeks European approval for nonacog beta pegol for hemophilia B

Anacor submits NDA for crisaborole for atopic dermatitis

FDA accepts for review sarilumab BLA for rheumatoid arthritis

FDA grants orphan drug and breakthrough therapy designations to setmelanotide

FDA clears IND application for pediatric trial of TB-403

FDA grants priority review for sNDA for Viekira Pak in genotype 1b HCV and cirrhosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...